Procalcitonin Monitoring Sepsis Study
MOSES
Procalcitonin Decrease Over 72 Hours and Outcome in Patients With Severe Sepsis or Septic Shock
1 other identifier
observational
858
1 country
13
Brief Summary
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2011
Typical duration for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2011
CompletedFirst Submitted
Initial submission to the registry
January 19, 2012
CompletedFirst Posted
Study publicly available on registry
February 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedMarch 17, 2015
March 1, 2015
2.2 years
January 19, 2012
March 13, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
28 day all cause mortality
participants will be followed up for 28 days
within 28 day safter inlclusion
Secondary Outcomes (1)
all-cause in-hospital mortality
mortality during hospital stay
Eligibility Criteria
adult patients with severe sepsis or septic shock in the emergency department, medical floor, ICU
You may qualify if:
- Adult patients (i.e. \>18 years of age) diagnosed with severe sepsis or septic shock as defined in Appendix 1, who are already in the ICU or come from the ED, other wards or directly from out of hospital
- Blood sample collection within 12 hours after diagnosis "severe sepsis or septic shock"No prior enrollment into this study
- Written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brahms AGlead
Study Sites (13)
University of California Davis Health System
Sacramento, California, 95817, United States
Northwestern University
Chicago, Illinois, 60611, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Saint Vincent Hospital
Worcester, Massachusetts, 01608, United States
Detroit Receiving Hospital
Detroit, Michigan, 48201, United States
Sinai Grace Hospital
Detroit, Michigan, 48201, United States
Henry Ford Health System
Detroit, Michigan, 48202, United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216, United States
New York Methodist Hospital
New York, New York, 11215, United States
Stony Brook University
New York, New York, 11794, United States
Carolinas Medical Center
Charlotte, North Carolina, 28203, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Biospecimen
EDTA plasma and serum samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nathan Shapiro, MD
Beth Israel Deaconess Medical Center
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 19, 2012
First Posted
February 1, 2012
Study Start
December 1, 2011
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
March 17, 2015
Record last verified: 2015-03